Secukinumab
Secukinumab
Immunoglobulin G1, anti-(human interleukin-17A (IL-17, cytotoxic T-lymphocyte-associated antigen 8)); human monoclonal AIN457 gamma1 heavy chain (230-215')-disulfide with human monoclonal AIN457 kappa light chain dimer (236-236'':239-239'')-bisdisulfide
Stoffgruppe
Immunsuppressivum (Interleukin-Inhibitor)
Halbwertszeit
27 Tage
Präparate